SRx Health Solutions, Inc. (NYSE American: SRXH) files a range of SEC documents that together outline its evolving strategy, capital structure and planned combination with EMJ Crypto Technologies Inc. (EMJX). On this page, investors can review current reports on Form 8-K, registration statements on Form S-1 and S-1/A, and other filings that describe material agreements, financing transactions and listing-status developments.
In its 8-K filings, the company discloses the Share Exchange and Asset Transfer Agreement to acquire EMJX, CCC Crypto Corp. and related intellectual property assets, including technology that uses artificial intelligence to predict outcomes from data sets. These reports also cover stockholder approvals for a future name change to EMJX, Inc. and a planned ticker change to EMJX, amendments to the Certificate of Incorporation to increase authorized common shares, and the designation of Series A Convertible Preferred Stock with detailed rights and conversion terms.
SRXH’s registration statements on Form S-1 and S-1/A provide additional information on private placements of Series A Convertible Preferred Stock and warrants, as well as an equity line of credit arrangement with Keystone Capital Partners, LLC. These documents explain how the company may raise capital through the issuance of equity and equity-linked securities, and they discuss risks associated with ownership of its securities. Filings also address NYSE American continued listing standards, including notices of non-compliance related to stockholders’ equity and the exchange’s acceptance of the company’s plan to regain compliance.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review them alongside AI-generated summaries that highlight key terms, structural features and risk considerations. This includes simplified explanations of complex documents such as 8-Ks describing material definitive agreements, S-1 registration statements detailing resale registrations and capital-raising arrangements, and governance-related amendments to the company’s charter and bylaws.
SRx Health Solutions, Inc. registered for resale up to 187,552,665 shares of common stock under a prospectus supplement dated February 26, 2026. The resale pool includes shares issuable on conversion or exercise from prior PIPE financings, exchangeable Canadian shares, private placement shares, service provider shares, and shares issued in a share exchange.
The company also reported receipt of a public Warning Letter from NYSE Regulation dated February 18, 2026, citing failures to obtain exchange listing approval and adequate shareholder approval related to approximately 7.5 million common shares issued upon conversion of Series A Convertible Preferred Stock. As of the report, all Preferred Shares have been converted or redeemed and no Preferred Shares remain outstanding.
SRx Health Solutions, Inc. reported receiving a public Warning Letter from NYSE American, indicating it failed to comply with Sections 301 and 713 of the exchange’s Company Guide. The issue stems from issuing approximately 7.5 million common shares upon conversion of Series A preferred stock between December 31, 2025 and January 23, 2026.
NYSE Regulation states the company did not obtain prior listing approval for these additional shares and did not secure sufficient shareholder approval for an issuance exceeding 20% of common stock outstanding. The exchange notes that future failures to meet listing requirements could lead to further action, including potential delisting proceedings. SRx Health says all Series A preferred shares have now been converted or redeemed, with none outstanding.
SRx Health Solutions Inc. reported net sales of $2.8 million and a net loss of $8.6 million for the quarter ended December 31, 2025, as it refocuses on its Halo premium pet food business after exiting its Canadian healthcare operations.
Gross profit was $1.1 million on cost of goods sold of $1.8 million, but heavy selling, general and administrative expenses of $4.8 million and interest and other expenses, including a $3.1 million loss on extinguishment of debt and a $0.5 million loss on digital assets, drove the loss. Cash rose to $13.1 million, helped by new equity and preferred stock financings, while convertible debt totaled $21.0 million. The company also invested $8.5 million into crypto assets and subsequently raised about $29.1 million through its equity line, significantly increasing shares outstanding to 298.2 million as of February 11, 2026.
SRx Health Solutions, Inc. has filed a prospectus supplement covering the resale by selling stockholders of up to 187,552,665 shares of common stock. These shares include stock underlying July and October PIPE securities, exchangeable shares, prior private placements, service provider awards, and a share exchange transaction.
Separately, the company redeemed all outstanding Series A preferred stock for an aggregate redemption price of approximately $21,772,500125,000,000 shares of common stock on an as-converted basis, which the company states is intended to improve balance sheet flexibility for potential M&A or returns of capital.
SRx Health Solutions, Inc. is registering up to 2,506,893,959 shares of common stock for resale by Keystone Capital Partners under a common share purchase agreement. The company will not receive proceeds from Keystone’s resales, but can receive cash when it sells shares to Keystone under the equity line.
Separately, SRx Health redeemed 17,418 shares of its Series A Convertible Preferred Stock for an aggregate redemption price of approximately $21,772,500, representing about 125,000,000 common shares on an as-converted basis. The preferred redemption and related common share cancellation are described as improving balance sheet flexibility for potential future M&A or returns of capital.
SRx Health Solutions, Inc. received a major shareholder disclosure from individual investor Kevin Egan. He reports beneficial ownership of 14,031,500 shares of SRx Health common stock, representing 5.0% of the class as of the event date 02/05/2026.
The filing states that Egan has sole power to vote and sole power to dispose of these 14,031,500 shares. He files in his individual capacity, indicates no membership in any group, and reports no ownership on behalf of other persons or subsidiaries.
SRx Health Solutions, Inc. filed a current report describing the full redemption of its Series A Convertible Preferred Stock. The company redeemed all outstanding preferred shares for an aggregate redemption price of approximately $21,772,500 under the terms of its certificate of designations.
According to the accompanying press release, the redeemed Series A Preferred Stock had represented about 125,000,000 shares of common stock on an as-converted basis, which are now canceled. The company previously issued 19,035 preferred shares in a private placement for roughly $15.23 million in proceeds. Management states that eliminating this class of preferred stock and the associated as-converted common shares improves capital structure flexibility for potential future investments or returning capital to shareholders.
SRx Health notes it has no undisclosed immediate plans for mergers and acquisitions as of the release date, but will continue to evaluate opportunities periodically. The company also expects to file its Form 10-Q for the quarter ended December 31, 2025 on February 13, 2026.
SRx Health Solutions, Inc. reports that NYSE American has accepted its plan to regain compliance with listing standards, allowing its common stock to continue trading during a plan period ending July 14, 2026. The company must give NYSE American quarterly updates on its progress toward the plan’s goals.
NYSE American previously notified the company that it fell below the continued listing requirement for stockholders’ equity of $4 million after SRx Health Solutions reported stockholders’ equity of ($45.9) million as of June 30, 2025, along with losses in three of its four most recent fiscal years ended December 31, 2024. The company states that it intends to regain compliance with Section 1003(a)(i) within the plan period.
SRx Health Solutions, Inc. filed a prospectus supplement covering the resale of up to 187,552,665 shares of common stock held by selling stockholders. These shares come from prior PIPE financings in July and October 2025, exchangeable shares issued in connection with SRx Health Solutions (Canada), a private placement, service provider share issuances, and shares issued under a share exchange with Halo Spin-Out SPV Inc.
The supplement includes a Current Report on Form 8-K describing stockholder written consents dated December 17, 2025. Stockholders approved a future name and ticker change to EMJX, a potential issuance of at least 20% of outstanding common stock for a transaction to acquire EMJ Crypto Technologies Inc., CCC Crypto Corp. and related AI-based intellectual property, an increase in the 2019 Incentive Award Plan share pool, the election of four directors, advisory approval of executive compensation, and ratification of Davidson and Company LLP as auditor. These actions were approved by holders of 45.42% of the company’s voting power as of the December 12, 2025 record date.
SRx Health Solutions, Inc. is registering up to 187,544,974 shares of common stock for resale by existing holders, including shares issuable from PIPE financings, exchangeable shares, private placements, service provider grants and a prior share exchange. The company will not receive proceeds from these resales, which could put pressure on the share price because the registered amount represents a meaningful portion of its public float.
The prospectus describes significant financing arrangements, including July and October PIPE deals, an equity line of credit that may allow sales of up to $1.0 billion of common shares, and a $20.0 million convertible note tied to that facility. It also highlights serious risks: the auditors have raised substantial doubt about the company’s ability to continue as a going concern, the Canadian subsidiary SRx Canada is in CCAA restructuring with asset sales under court supervision, and the Halo pet business has recurring losses and intense competitive and operational pressures.